{"entity":{"id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","aka":[],"tldr":"A phase 2 trial of Decitabine, Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. is a phase 2 interventional study registered as NCT05201066 by Novartis Pharmaceuticals, with 33 participants enrolled, started 2023-02-28 and due to reach its primary completion in 2028-02-14. Interventions recorded: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax and INQOVI (oral decitabine).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05201066","url":"https://clinicaltrials.gov/study/NCT05201066"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds"],"sections":[],"technologies":[],"targets":[],"drugs":["decitabine","azacitidine","venetoclax","spartalizumab","sabatolimab"],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05201066","phase":"2","setting":"An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT05201066","source":"https://clinicaltrials.gov/study/NCT05201066","fetchedAt":"2026-10-07T16:53:36.501Z","studySha256":"5c377783e940eebd8c50e8b56640e1a711e0ca09c0963b1c7ab1d1ae7b6ff2f8","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-22","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"12 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":33,"enrolmentType":"ACTUAL","siteCount":24,"recruitingSiteCount":0,"countries":["Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Italy","Japan","Malaysia","Spain","Switzerland","Turkey (Türkiye)","United States"]}],"started":"2023-02-28","startedType":"actual","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05201066/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/"},{"id":"sabatolimab","kind":"drug","name":"Sabatolimab","route":"/drugs/sabatolimab/"},{"id":"spartalizumab","kind":"drug","name":"Spartalizumab","route":"/drugs/spartalizumab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}